These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12117452)

  • 1. Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity.
    Ruilope LM; Coca A; Banegas JR; Pablos JL; Luque M
    Curr Hypertens Rep; 2002 Aug; 4(4):261-4. PubMed ID: 12117452
    [No Abstract]   [Full Text] [Related]  

  • 2. The ever growing story of cyclo-oxygenase inhibition.
    Rodríguez LA; Patrignani P
    Lancet; 2006 Nov; 368(9549):1745-7. PubMed ID: 17113403
    [No Abstract]   [Full Text] [Related]  

  • 3. [Insights and views about cardiovascular safety of COX2 inhibitors].
    Wallentin L
    Lakartidningen; 2005 Feb 28-Mar 6; 102(9):666, 668, 671. PubMed ID: 15804041
    [No Abstract]   [Full Text] [Related]  

  • 4. Discontinuation of Vioxx.
    Nutt DJ
    Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular events and COX-2 inhibitors.
    Singh G
    JAMA; 2001 Dec; 286(22):2810-1; author reply 2811-2. PubMed ID: 11735748
    [No Abstract]   [Full Text] [Related]  

  • 6. [A step back or training pain?].
    Raeder J
    Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2050-1. PubMed ID: 16100553
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased risk of cardiovascular events with coxibs and NSAIDs.
    Scott DG; Watts RA
    Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
    [No Abstract]   [Full Text] [Related]  

  • 8. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.
    Dubois RW; Melmed GY; Henning JM; Laine L
    Aliment Pharmacol Ther; 2004 Jan; 19(2):197-208. PubMed ID: 14723611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 inhibitors: little or no GI protection, increased risk of cardiovascular events, high cost, and other class-less effects.
    Curtiss FR
    J Manag Care Pharm; 2005 Sep; 11(7):590-3. PubMed ID: 16137219
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective cyclo-oxygenase inhibitors.
    Wilcock M; MacKenzie I
    Lancet; 2001 Aug; 358(9280):510. PubMed ID: 11515521
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on Jüni P, Dieppe P. Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDs.
    Stichtenoth DO; Frölich JC
    Age Ageing; 2004 Sep; 33(5):521. PubMed ID: 15315931
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 14. Painful lessons.
    Nat Rev Drug Discov; 2005 Oct; 4(10):800-3. PubMed ID: 16237842
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really Anti-Inflammatory?
    Khan S; Andrews KL; Chin-Dusting JPF
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arthritis medicines and cardiovascular events--"house of coxibs".
    Topol EJ
    JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
    [No Abstract]   [Full Text] [Related]  

  • 17. [Selective inhibitors of cyclooxigenase-2 (Coxibs) and cardiovascular morbidity].
    Ruilope LM; Coca A
    Med Clin (Barc); 2002 Feb; 118(6):219-21. PubMed ID: 11864545
    [No Abstract]   [Full Text] [Related]  

  • 18. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA; Schroy PC
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract]   [Full Text] [Related]  

  • 19. COX-2 inhibitors and cardiovascular toxicity: a class effect?
    Laible B
    S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
    [No Abstract]   [Full Text] [Related]  

  • 20. Controversies in COX-2 inhibitor therapy: closing remarks.
    Abramson SB; Furst DE; Hochberg MC; Patrono C
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S77-80. PubMed ID: 11695257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.